Literature DB >> 2214610

[HIV-1 antigenemia and T-cell activation in HIV-1 infected patients].

T Harrer1, B Wolf, W Kersten, W Schwarz, D Bergner, J R Kalden.   

Abstract

In order to study a supposed association between T-cell activation in vivo and HIV-1-antigenemia in HIV-1-infected patients, the detection of p24-antigen in sera was correlated to serum levels of beta-2-microglobulin and C1q-binding immune complexes. Anti-p24-antibodies and the urinary excretion of neopterin were also analysed. In 24 of 80 patients (30%) p24-antigen could be detected, and in 15 of 59 (25.4%) there was a loss of anti-p24-antibodies. Tests revealed elevated serum levels of beta-2-microglobulin in 58 of 80 patients (72.5%), elevated levels of C1q-binding immune complexes in 15 of 66 (22.7%), and increased excretion of neopterin in 52 of 60 (86.7%). Detection of p24-antigen, loss of anti-p24-antibodies, serum levels of beta-2-microglobulin, and urinary excretion of neopterin were significantly correlated to advanced stages of HIV-1 infection. Patients with p24-antigen in the serum showed significantly more frequently elevated serum levels of beta-2-microglobulin and no significant association with increased urinary excretion of neopterin. Because of the high proportion of patients with elevated serum levels of beta-2-microglobulin and increased excretion of urinary neopterin in the absence of detectable p24-antigen in serum, we could not correlate HIV-1-antigenemia to T-cell activation in vivo.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2214610     DOI: 10.1007/bf01662783

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  18 in total

1.  The Walter Reed staging classification for HTLV-III/LAV infection.

Authors:  R R Redfield; D C Wright; E C Tramont
Journal:  N Engl J Med       Date:  1986-01-09       Impact factor: 91.245

Review 2.  [Beta-2-microglobulin. Today's knowledge and diagnostic possibilities].

Authors:  U Uthmann; H P Geisen
Journal:  Dtsch Med Wochenschr       Date:  1981-06-12       Impact factor: 0.628

3.  Detection of lymphocytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization.

Authors:  M E Harper; L M Marselle; R C Gallo; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

4.  Biologically diverse molecular variants within a single HIV-1 isolate.

Authors:  A G Fisher; B Ensoli; D Looney; A Rose; R C Gallo; M S Saag; G M Shaw; B H Hahn; F Wong-Staal
Journal:  Nature       Date:  1988-08-04       Impact factor: 49.962

5.  Elevated beta 2-microglobulin and lysozyme levels in patients with acquired immune deficiency syndrome.

Authors:  M H Grieco; M M Reddy; H B Kothari; M Lange; E Buimovici-Klein; D William
Journal:  Clin Immunol Immunopathol       Date:  1984-08

6.  Circulating immune complexes in patients with acquired immune deficiency syndrome contain the AIDS-associated retrovirus.

Authors:  W J Morrow; M Wharton; R B Stricker; J A Levy
Journal:  Clin Immunol Immunopathol       Date:  1986-09

7.  HIV-specific cytotoxic T lymphocytes in seropositive individuals.

Authors:  B D Walker; S Chakrabarti; B Moss; T J Paradis; T Flynn; A G Durno; R S Blumberg; J C Kaplan; M S Hirsch; R T Schooley
Journal:  Nature       Date:  1987 Jul 23-29       Impact factor: 49.962

8.  Theoretical implications of cellular immune reactions against helper lymphocytes infected by an immune system retrovirus.

Authors:  G Reibnegger; D Fuchs; A Hausen; E R Werner; M P Dierich; H Wachter
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

9.  Extensive variation of human immunodeficiency virus type-1 in vivo.

Authors:  M S Saag; B H Hahn; J Gibbons; Y Li; E S Parks; W P Parks; G M Shaw
Journal:  Nature       Date:  1988-08-04       Impact factor: 49.962

10.  Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma.

Authors:  C Huber; J R Batchelor; D Fuchs; A Hausen; A Lang; D Niederwieser; G Reibnegger; P Swetly; J Troppmair; H Wachter
Journal:  J Exp Med       Date:  1984-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.